Navigation Links
Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
Date:8/21/2008

neys, leading to inflammation, the formation of disfiguring nodules (tophi), intermittent attacks of severe pain (acute flares), and kidney damage (nephropathy). While gout is a treatable condition, there are limited treatment options and a number of adverse effects are associated with current therapies. No new therapies have been approved by the FDA for the treatment of hyperuricemia associated with gout in the past 40 years

About RDEA594

RDEA594, our lead product candidate for the treatment of gout, is a major metabolite of RDEA806, our lead non-nucleoside reverse transcriptase inhibitor (NNRTI) in clinical development for the treatment of HIV. RDEA594 does not have antiviral activity and is believed to be responsible for the uric acid-lowering effects observed following administration of RDEA806 to over 100 subjects in Phase 1 and Phase 2 clinical trials. In Phase 1 studies of RDEA806 in normal healthy volunteers, increased urinary excretion of uric acid was observed in the first 24 hours after dosing, with statistically significant, exposure-dependent, decreases in serum uric acid of 35% to 50% observed during multiple dosing out to 14 days.

About RDEA806

RDEA806 is a novel NNRTI for the potential treatment of HIV infection. Based on preclinical and clinical studies to date, we believe that RDEA806 may have important competitive advantages compared to currently available NNRTIs. These include the potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R)) and other currently available NNRTIs; a high genetic barrier to resistance; limited pharmacokinetic interactions with other drugs; no reproductive toxicity based on animal studies; and the potential to be readily co-formulated in a single pill with other HIV antiviral drugs, such as Truvada(R) (emtricitabine and tenofovir) from Gilead Sciences, Inc, which is important for patient compliance.

A
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... CHICAGO, Ill. , Sept. 22, 2014 /PRNewswire/ ... data from several clinical studies evaluating potential new ... presented at the upcoming 2014 European Society of ... Madrid, Spain . Data being ... evaluating the safety and efficacy of veliparib (ABT-888), ...
(Date:9/22/2014)... DIEGO , Sept. 22, 2014 Arena Pharmaceuticals, ... company is scheduled to present a corporate overview and ... on Friday, September 26, 2014, at 11:30 a.m. Eastern ... Hotel in New York City . ... will be available under the investor relations section of ...
(Date:9/22/2014)... , September 22, 2014 ... Line Development Market by Product (Equipment, Media and Reagents), ... Engineering & Regenerative medicine, Toxicity Testing, Research, Drug ... published by MarketsandMarkets, analyzes and studies the major ... Browse 114 market data tables and 64 ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4
... PARSIPPANY, N.J., Jan. 31, 2011 PDI, Inc. (Nasdaq: ... officer, is scheduled to present at the UBS 21st Annual Global ... at the Grand Hyatt New York. The live ... company,s website at http://www.pdi-inc.com . The webcast will be archived ...
... Calif., Jan. 31, 2011 OXIS International, Inc., (OTC ... today announced highly favorable final results from an initial ... patent-pending ERGOFLEX™ joint health formula, launched commercially ... of pain was statistically significant after as little as ...
Cached Medicine Technology:Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 2Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 3Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 4
(Date:9/22/2014)... WI (PRWEB) September 22, 2014 ... in the United States, promotes National Self-Improvement ... believes that all individuals should have access to ... in aging. , The demand for products that ... longer than ever before. For over six years, ...
(Date:9/22/2014)... Va. (PRWEB) September 22, 2014 ... the nation’s leading nonprofit authority on the ... healthcare information exchange, announced findings from its recent ... Health Plan Identifier (HPID) within electronic transactions adopted ... (HIPAA). WEDI conducted the survey from August 20 ...
(Date:9/22/2014)... MONDAY, Sept. 22, 2014 (HealthDay News) -- Two new ... Administration (FDA) may provide some relief for people with ... to a new study. One device -- the ... other device -- the Cerena -- is meant to ... FDA news release. "Patients have been looking for ...
(Date:9/22/2014)... 22, 2014 Pain does not need to ... a user- and reader-friendly book designed to guide the individual ... living. This inspirational book is written to help the reader ... a way to regain a pain-free life — a daily ... pain. , Chronic pain has become an epidemic, with over ...
(Date:9/22/2014)... 22, 2014 PCI (Project Concern ... to equip women around the world with tools and ... the Women Empowered (WE) Initiative announced at the CGI ... groups to pool their savings, invest in their own ... solution to ending poverty in the world, and through ...
Breaking Medicine News(10 mins):Health News:Quincy Bioscience Promotes National Self-Improvement Month 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 3Health News:Noninvasive Devices May Help Migraines, FDA Says 2Health News:Naturopathic Doctor Inspires and Guides Those Who Suffer with Chronic Pain, Pointing the Way Back to Pain-free Living 2Health News:PCI Announces New Effort to Empower 250,000 Women Worldwide at 2014 Clinton Global Initiative (CGI) Annual Meeting 2Health News:PCI Announces New Effort to Empower 250,000 Women Worldwide at 2014 Clinton Global Initiative (CGI) Annual Meeting 3
... a young Indian American is hard put to find a ... South Asians are listed in the US Bone Marrow registry. ... a disease known as Acute Myelogenous Leukemia (or AML), a ... Asian community has come together nationwide to help him and ...
... International Diabetes Federation (IDF) today called for projects that ... with diabetes and to implement practical solutions for improving ... as BRIDGES (Bringing Research in Diabetes to Global Environments ... Congress in Cape Town, South Africa and was officially ...
... ice sheet to break up, even though the air over ... at least a century, according to a new study ... ,As part of their study, the team led by ... how high the ice had deposited boulders in Antarctica's Framnes ...
... Echinacea, a medicinal herb that came to prominence thanks to its ... catching a cold, a wide-scale study has confirmed. ,Taking ... percent and may also shorten the duration of a cold almost ... Sunday in the July issue of the journal The Lancet Infectious ...
... studies have found that new adjuvant treatments for breast ... Published in the August 1, 2007 issue of Cancer, ... studies looked at the cost-effectiveness of different drugs for ... ,In a Canadian economic study of estrogen ...
... Six World Heritage sites, including Mount Everest, could be at ... experts and groups . ,Urging the United Nations ... the Climate Justice Programme have petitioned the global body to ... that have signed the UN World Heritage Convention have a ...
Cached Medicine News:Health News:South Asians Seek Bone Marrow for Young Indian American 2Health News:The International Diabetes Federation Launches US$ 10 Million Grant to Improve Diabetes Care 2Health News:The International Diabetes Federation Launches US$ 10 Million Grant to Improve Diabetes Care 3Health News:Sioux Herb Confirmed as Shield Against Colds 2Health News:New Adjuvant Breast Cancer Treatments Found Cost-effective 2Health News:Everest, Five Other World Heritage Sites Face Climate Change Risk 2
Indications For Usage: ,Airway management during anesthesia or short-term surgical procedures....
Indications For Usage: , When patient's head is in an extended or flexed position When patient will be turned over. , Long-term cases where maintenance of an airway is critical. , Neurosurgical pr...
Indications For Usage: ,Airway management during pediatric surgical procedures and intensive care....
... Detector/Clamp adds air detection and automatic clamping capability ... Fluid Warmer., ,The potential of air embolism ... known. Currently, health care professionals rely primarily on ... has lead to the safe use of the ...
Medicine Products: